Floatz logo

Humax-Cd20

Diffuse Large B-Cell Lymphoma

SCRI Development Innovations, LLCmonoclonal_antibodyPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

253 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 2/3A
Melphalan
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Adriamycin
Beth Israel Deaconess Medical Center
Phase 4BBB
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
74 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →